Simulect Injection 20 Mg 1 Vial
₨ 85,000
Simulect 20 mg Injection (Basiliximab) is a monoclonal antibody used to prevent acute organ rejection in kidney transplant recipients. Administered intravenously around the time of transplant, it targets the CD25 receptor on activated T-cells—blocking the IL-2 pathway and reducing immune response against the new kidney.
Each single-use vial contains 20 mg of basiliximab in solution. Doctors typically prescribe two doses: one within 2 hours after transplant and a second dose on day 4 post-transplant. This regimen offers effective rejection prevention without continuous monoclonal therapy.
Simulect works swiftly to suppress immune activity, thereby improving graft survival and reducing reliance on higher doses of standard immunosuppressants. It complements corticosteroids and calcineurin inhibitors like tacrolimus.
Healthcare providers administer Simulect via IV infusion in a hospital setting. Medical staff monitor patients closely during and after infusion, paying attention to potential infusion-related reactions.
Store unopened Simulect vials in the refrigerator at 2 °C to 8 °C, protected from light. Do not freeze. Once opened, no freezer storage—use per medical recommendation.
Simulect 20 mg Injection (Basiliximab)
Simulect 20 mg Injection (Basiliximab) is a targeted immunosuppressive therapy used to prevent acute rejection in kidney transplant recipients. It works by blocking the interleukin-2 (IL‑2) receptor α-chain (CD25) on activated T-lymphocytes. This action prevents their proliferation, helping preserve the transplanted kidney without broadly suppressing the immune system.
Dosing Schedule
- First dose: Given within 2 hours before or immediately after transplant surgery
- Second dose: Administered on day 4 post-transplant
This two-dose regimen provides early and effective graft protection without the need for prolonged basiliximab exposure.
Benefits of Simulect
Simulect improves transplant outcomes by reducing the risk of acute rejection. It also enables the use of lower doses of steroids and calcineurin inhibitors such as tacrolimus. When combined with standard immunosuppressants, Simulect helps achieve optimal protection while minimizing systemic side effects.
Administration & Monitoring
- Administered by a trained professional through IV infusion over approximately 20 minutes
- Vital signs such as blood pressure and heart rate are monitored during and after infusion
- Patients are observed for infusion-related reactions like rash or mild fever
- Follow-up includes renal function tests and immunosuppressive drug level checks
Storage & Handling
- Store vials in a refrigerator (2 °C to 8 °C), protected from light
- Do not freeze
- Use prepared solution promptly, following healthcare provider guidelines
Safety & Side Effects
Simulect is generally well tolerated. However, some patients may experience:
- Hypersensitivity reactions during infusion
- Increased risk of infections
- Mild gastrointestinal symptoms
In rare cases, serious allergic or immune-mediated reactions may occur. Routine monitoring is essential to detect signs of infection or organ rejection early.
Indication
Simulect is indicated for the prevention of acute rejection in kidney transplantation. Its targeted mechanism makes it a valuable part of modern transplant protocols, especially during the high-risk early post-operative period.
For more transplant medications and immunosuppressants, visit our
Medicine Category.
To explore all healthcare supplies, browse our full catalog at the
online pharmacy shop.
Related products
Reviews
Clear filtersThere are no reviews yet.